Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
VALENCIA, Calif., Nov. 09, 2016 -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) today announced that MannKind and Sanofi have entered into an agreement with the following terms:
- The promissory note and security agreement between MannKind and Aventisub LLC, a Sanofi affiliate, are terminated, with Aventisub agreeing to forgive the full outstanding loan balance of $71.56 million.
- MannKind is also relieved from its obligation to pay $0.5 million in previously uncharged costs related to the collaboration.
- Sanofi will purchase $10.2 million worth of insulin from MannKind in early December as part of its preexisting commitment to purchase insulin following termination of the collaboration and MannKind’s exercise of a “put” option.
- The balance of the insulin “put” option ($30.6 million) is accelerated with Sanofi completing the cash payment of $30.6 million to MannKind by January 9, 2017. This payment will be made without MannKind being required to deliver any insulin to Sanofi.
- All issues arising out of the license and collaboration agreement, the supply agreement, the promissory note, the security agreement and the transition agreement are resolved.
About MannKind Corporation
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.
Company Contact: Rose Alinaya SVP, Finance 661-775-5300 [email protected]
